Vita Therapeutics Raises $32 Million

Vita Therapeutics Raises $32 Million

Vita Therapeutics Raises $32 Million in Oversubscribed Series A Financing Led by Cambrian Biopharma to Advance the Development of Therapies to Treat Muscular Dystrophies

BALTIMORE, Md. – Jun. 23, 2021 –Vita Therapeutics, a cell engineering company harnessing the power of genetics to develop cellular therapies that follow an autologous and universal hypoimmunogenic approach, today announced the completion of an oversubscribed $32 million Series A. The financing was led by Cambrian Biopharma with participation from Kiwoom Bio, SCM Life Sciences, and Early Light Ventures.

URL link to full story
https://uploads-ssl.webflow.com/60b7d4030b7086a22a392c2c/60d2409e09416f060e643753_VitaTxSeriesAPRFinal.pdf
Media Contact
Helen Shin
(609) 339-5126
Comments are closed.